SCYNEXIS: FDA Grants Priority Review For SNDA To Expand Label Of BREXAFEMME

SCYNEXIS, Inc. (SCYX) announced the FDA has accepted the company's submission of a supplemental New Drug Application to expand the label of BREXAFEMME to include the prevention of recurrent vulvovaginal candidiasis. The Submission has been granted priority review and given a target regulatory decision date of November 30, 2022.

SCYNEXIS said the regulatory submission for the label extension is supported by positive data from the phase 3 CANDLE study. The company will present CANDLE study results in the current week at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting.

BREXAFEMME is an oral antifungal approved for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said it now intends to review only a small subset of new emergency use authorization or EUA requests for diagnostic tests. As per an updated COVID-19 test policy with a view to ensure continued access to tests, the regulator further urged developers of all test types seeking marketing authorization to pursue traditional premarket review for most test types. Netflix, Inc. said it is adding a new feature to offer a more personalized mobile games experience on the platform. In a statement, Sophia Yang, Product Manager, Mobile Games, said the company is rolling out the ability to create game handles, with which members will be able to create a unique public username. This can be used across all Netflix games. General Motors Co. has delayed its plan to require employees to return to office many days a week until next year, reports said citing an internal memo signed by CEO Mary Barra. Last week, the company had announced that corporate workers would be required to return to respective offices at least three days a week, beginning later this year, as the COVID-19 pandemic eases.
Follow RTT